ALCHEMIA LAUNCHES INTO INDIA

Written on the 4 June 2013

ALCHEMIA LAUNCHES INTO INDIA

BRISBANE drug development company Alchemia Limited (ASX: ACL) has launched a deep vein thrombosis prevention drug into India following success in the United States.

Fondaparinux is an injectable coagulant approved in the United States for the prevention and treatment of deep vein thrombosis after knee or hip surgery. It will be sold and marketed in India by international marketing partner Dr Reddy’s Laboratories Inc. under the name Fondared.

The drug is a generic version of GlaxoSmithKline’s Arixtra which achieved Indian sales of around $US2.7 million during the 2012 calendar year.

ACL expects to receive 25% of all profits from sales in India with the same economies from sales from any further territories outside the United States.

Dr Reddy’s Laboratories has filed a regulatory submission in Europe seeking marketing approval for the drug in key European markets.

CEO Charles Walker says the launch represents a milestone for the company.

“This launch represents the first for our fondaparinux outside of the U.S.,” he says.

“We look forward to fondaparinux’s expansion into additional territories.”

Meanwhile ACL’s pipeline of oncology products continues to develop.

The company recently announced the final recruitment of 390 patients for its most advanced cancer drug, HA-Irinotecan, which is in Phase III for the treatment of metastatic colorectal cancer.

The treatments are built on targeted cancer delivery which is used to selectively target cancer drugs to tumours.


Latest News

EVERYTHING YOU NEED TO KNOW ABOUT THE NATIONAL BROADBAND NETWORK

THE National Broadband Network (NBN) is more than an internet connection, it is an opportunity to transform your b...

VOLATILE INDUSTRY CLIPS FLIGHT CENTRE'S WINGS

DESPITE achieving record sales in the first half, Flight Centre Travel Group (ASX: FLT) profit has suffered the ef...

ARDENT TAKES $95.2 MILLION HIT FROM DREAMWORLD TRAGEDY

ARDENT Leisure has taken a $95.2 million write-down on the value of its Dreamworld theme park following the tragedy t...

AGENT EXITS, LOW LISTINGS HURT MCGRATH

PROFITS have dived 72 per cent at real estate group McGrath (ASX:MEA) to $2.4 milllion on the back of low property...

Related News

EVERYTHING YOU NEED TO KNOW ABOUT THE NATIONAL BROADBAND NETWORK

THE National Broadband Network (NBN) is more than an internet connection, it is an opportunity to transform your b...

WHY EMPLOYEE-OWNED COMPANIES ARE BEATING ASX200 SHARE PRICES

EMPLOYEE-owned companies command a higher share price than their publicly listed peers, reaping a 17 per cent prem...

RISE OF THE MACHINES HAS WORKERS SWEATING

UP TO 3.8 million Australian workers are fearful their job may soon be terminated by a robot, a new survey has shown....

LESS TALK, MORE SMALL BUSINESS ACTION IN 2017

THE future growth and prosperity of Australian SMEs could be undermined if governments lose sight of the sector...

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter